



CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATIONS M&A MARKET

Published on Alvarez & Marsal | Management Consulting | Professional Services

(<https://www.alvarezandmarsal.com>)

December 02, 2024

The global Contract Development and Manufacturing Organisation (CDMO) market, which helps Pharmaceutical and MedTech companies efficiently develop, manufacture, and bring products to market, is valued at \$230 billion in 2024, and is anticipated to grow at a CAGR of 8.5% to reach \$358 billion by 2029 [1][2].

Key factors propelling the global Pharmaceutical CDMO market:

- **Agile Manufacturing Practices:** CDMOs are adopting continuous manufacturing practices, offering flexible and cost-effective solutions for Pharma clients that follow the traditional batch manufacturing model.
- **Complex and Personalised Medicines:** The shift towards personalised medicines is increasing outsourcing to CDMOs who have specialised development and manufacturing capabilities in place.
- **End-to-End Services:** CDMOs offering comprehensive support from early-stage development to manufacturing across various modalities helps streamline processes and reduce time-to-market for new therapies.
- **Regulatory Expertise:** CDMOs help Pharma companies navigate complex regulatory frameworks, reducing compliance risks, costs, and increasing reliance on CDMO partners.

Principal forces driving the global Medical Technology CDMO market:

- **Outsourcing by OEMs:** MedTech OEMs are increasingly outsourcing development and manufacturing to CDMOs to focus on core competencies, improving efficiency and providing upfront capital savings.
- **Regionalisation of Supply Chains:** Pressures for OEMs to regionalise supply chains to limit disruptions and reduce their carbon footprint is increasing the demand for CDMOs with a local presence.
- **Technological Advancements:** Many CDMOs have specialised technological capabilities that OEMs rely on to develop innovative solutions, supporting outsourced spending across high growth therapy areas.
- **Regulatory Compliance:** Strict EU and UK regulations are driving OEMs to outsource to CDMOs that can navigate complex regulatory environments efficiently, reducing costs and compliance risks.

To learn more about the key M&A trends taking shape this year in the CDMO space, read our latest paper.

[DOWNLOAD THE FULL PAPER](#)

If you would like to know more about the CDMO M&A landscape after reading this paper, or have any other questions on the wider healthcare space, please do get in touch with [Al-Munther Sultan](#). We would be delighted to discuss this report with you, including any implications these current and longer-term market themes may have on your business and overall shareholder objectives.

Source:

[1] Grand View Research - Pharmaceutical CDMO Market Size & Trends

[2] MarketsandMarkets - Medical Device Contract Manufacturing Market

Source URL:<https://www.alvarezandmarsal.com/insights/contract-development-and-manufacturing-organisations-ma-market>

Authors:

Al-Munther Sultan

Jane Hartley

Claire Edwards

Chris Savidge

Steven Young